Novavax and the Vaccine Alliance (Gavi) announced today that they have reached an agreement relating to the Advance Purchase Agreement (APA) decided in 2021 concerning Novavax's COVID-19 prototype vaccine (NVX-CoV2373).

This agreement puts an end to the ongoing arbitration related to the PPA.

' Novavax is pleased to have reached this agreement with Gavi as it gives us the opportunity to continue working together toward our shared mission of ensuring equitable access to safe and effective vaccines, ' said John C. Jacobs, President and CEO of Novavax.

''We look forward to a long-term partnership with Gavi to provide continued access to our protein-based, mRNA-free COVID-19 vaccine,'' he added.

Copyright (c) 2024 CercleFinance.com. All rights reserved.